EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nuvation Bio's enterprise value is $194.67 Mil.
Nuvation Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Nuvation Bio's EV-to-Revenue for today is .
The historical rank and industry rank for Nuvation Bio's EV-to-Revenue or its related term are showing as below:
NUVB's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.96 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-13), Nuvation Bio's stock price is $3.25.
Nuvation Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Nuvation Bio's PS Ratio for today is .
Nuvation Bio EV-to-Revenue Historical Data
The historical data trend for Nuvation Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nuvation Bio's EV-to-Revenue
For the Biotechnology subindustry, Nuvation Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's EV-to-Revenue falls into.
Nuvation Bio's current Enterprise Value is $194.67 Mil.
Nuvation Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NYSE:NUVB) EV-to-Revenue Explanation
Nuvation Bio's share price for today is $3.25.
Nuvation Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Nuvation Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVB has been successfully added to your 